Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy
- Details
- Category: Pfizer
Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University Medical Center.
Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises
- Details
- Category: Novo Nordisk
The International Committee of the Red Cross (ICRC), the Danish Red Cross (DRC) and Novo Nordisk today announced a partnership to tackle the growing issue of chronic diseases that affect millions of people living in humanitarian crises around the world.
FDA grants Breakthrough Therapy Designation for Roche's Hemlibra in haemophilia A without inhibitors
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors. Breakthrough Therapy Designation is designed to accelerate the development and review of medicines intended to treat a serious condition with preliminary evidence that indicates they may demonstrate a substantial improvement over existing therapies.
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
- Details
- Category: Novartis
Novartis announces a five-year commitment to the fight against malaria in conjunction with the 7th Multilateral Initiative on Malaria Conference and the Malaria Summit of the Commonwealth Heads of Government meeting. Further, the company releases new African research on progress and remaining challenges toward the 2030 malaria elimination targets, together with Elimination 8 and the KEMRI-Wellcome Trust program.
Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) have announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes.
Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) today announced a worldwide collaboration with Janssen Pharmaceuticals, Inc. (Janssen) on a Factor XIa (FXIa) inhibitor program that includes the development and commercialization of Bristol-Myers Squibb's Factor XIa (FXIa) inhibitor, BMS-986177, an investigational anticoagulant compound being studied for prevention and treatment of major thrombotic conditions.
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
- Details
- Category: GlaxoSmithKline
GSK and Orchard Therapeutics have announced a strategic agreement, under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard, securing the continued development of the programmes and access for patients. This acquisition strengthens Orchard's position as a global leader in gene therapy for rare diseases.
More Pharma News ...
- Bristol-Myers Squibb and Harvard announce new fibrosis research collaboration
- Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
- Boehringer Ingelheim and OSE Immunotherapeutics announce global immuno-oncology partnership to develop a pioneering checkpoint inhibitor for the treatment of advanced solid tumors
- Combining tradition with modernity: Bayer hones its brand profile
- Pfizer and Allogene Therapeutics enter into asset contribution agreement for Pfizer's allogeneic CAR T immuno-oncology portfolio
- Merck partners with Medisafe to help improve medication adherence for cardiometabolic patients
- GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business